Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qyuns Therapeutics CoHKSE:02509 -1.84%9 Gross Margin % is 89.39% as of Dec. 2025, which is 22% above its 10-year median of 73.30. GuruFocus rates HKSE:02509 with a GF Score™ of 9/100. The stock has 5 warning signs investors should review. Among 735 Biotechnology companies, Qyuns Therapeutics Co ranks better than 81.77% on this metric.
Qyuns Therapeutics Co (HKSE:02509) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Qyuns Therapeutics Co had a gross margin of 89.39% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Qyuns Therapeutics Co Gross Margin % Related Terms
Qyuns Therapeutics Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for Qyuns Therapeutics Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02509 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Qyuns Therapeutics Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qyuns Therapeutics Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Qyuns Therapeutics Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Qyuns Therapeutics Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Qyuns Therapeutics Co (HKSE:02509) has a Gross Margin % of 89.39% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Qyuns Therapeutics Co and its competitors. This is 22% above median its historical median of 73.30. Over the past decade, Qyuns Therapeutics Co's Gross Margin % has ranged from 58.06 to 88.54. According to the industry distribution chart, Qyuns Therapeutics Co ranks #134 out of 735 companies in the Biotechnology industry, placing it in the top 18.2%.
Is Qyuns Therapeutics Co's Gross Margin % too high?
Qyuns Therapeutics Co's current Gross Margin % of 89.39% is 22% above median its 10-year median of 73.30. Over the past 10 years, this metric has ranged from a low of 58.06 to a high of 88.54. The Biotechnology industry median Gross Margin % is 60.91. Qyuns Therapeutics Co's value of 89.39% is 46.8% above this industry median. Based on the distribution chart, Qyuns Therapeutics Co ranks #134 out of 735 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Qyuns Therapeutics Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Qyuns Therapeutics Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Qyuns Therapeutics Co ranks #134 out of 735 companies for Gross Margin %. This places Qyuns Therapeutics Co in the top 18% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Qyuns Therapeutics Co's value of 89.39% is 46.8% above this benchmark. Historically, Qyuns Therapeutics Co's own Gross Margin % has ranged from 58.06 to 88.54 over the past decade. While the company's 10-year median is 73.30 vs. the industry median of 60.91, Qyuns Therapeutics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qyuns Therapeutics Co's current Gross Margin % of 89.39% is 46.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Qyuns Therapeutics Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qyuns Therapeutics Co's current Gross Margin % is 89.39%, which is 22% above median its own 10-year median of 73.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qyuns Therapeutics Co stock overvalued right now?
Qyuns Therapeutics Co (HKSE:02509) has a current Gross Margin % of 89.39%. The current Gross Margin % is 89.39%, which is 22% above median its 10-year median of 73.30 and 46.8% above the Biotechnology industry median of 60.91. Qyuns Therapeutics Co's overall GF Score™ is 9/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Qyuns Therapeutics Co (HKSE:02509), the current Gross Margin % is 89.39% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Qyuns Therapeutics Co Ltd is a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory, and digestive diseases. The group is principally engaged in the research and development, manufacturing, and commercialisation of biologic therapies for autoimmune and allergic diseases. Key revenue is generated from the PRC.
9GF Score
Get the complete analysis for HKSE:02509
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02509 has been successfully added to your 
